ETD

Digital archive of theses discussed at the University of Pisa

 

Thesis etd-11182019-144740


Thesis type
Tesi di specializzazione (5 anni)
Author
TARANTINI, GAIA
URN
etd-11182019-144740
Thesis title
Intraductal papillary mucinous neoplasms of the pancreas: safety of MR imaging protocol over 10 years follow-up. Preliminary data.
Department
RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Course of study
RADIODIAGNOSTICA
Supervisors
relatore Prof. Caramella, Davide
relatore Dott. Boraschi, Piero
Keywords
  • pancreas
  • IPMN
Graduation session start date
14/12/2019
Availability
Withheld
Release date
14/12/2089
Summary
Purpose
To evaluate the safety of a MR imaging procotol in assessing the evolution of individuals with branch duct - intraductal papillary mucinous neoplasms (BD-IPMN) without “worrisome features” (WF) and/or “high risk stigmata” (HRS) at the time of the diagnosis with a follow-up of at least 10 years.
Methods and Materials
A revision of a prospectively collected radiological database including a total number of 600 patients who were investigated and diagnosed with IPMN at our Department since 2008 was performed. Among them, we selected a group of patients with “presumed” diagnosis of BD-IPMN at MRI/MRCP. Inclusion criteria were the absence of WF and/or HRS at the time of diagnosis and a radiological follow-up with abdominal MRI/MRCP for at least 10 years.
Results
Our final cohort included a series of sixty-nine patients fulfilling all the inclusion criteria. During surveillance, the cysts remained dimensionally unchanged or slightly reduced in size in 18/69 (26%) and 3/69 (4,3%) cases, respectively. In the remaining 48/69 (69,5%) cases, cyst enlargement was demonstrate with median annual growth rate of 0,97± 0,87 mm/yr (range 0,13-5,0). WF and HRS developed in 10/69 (14,5%) and 3/69 (4,3%) cases, respectively. In our study group only five patients (7,2%).
Conclusion
In our study group the incidence of pancreatic cancer in patients with BD-IPMN is 2,9%. Our data support the safety of our surveillance MR imaging protocol.
File